Johnson & Johnson Showcases New Scientific Evidence and Strengthens Leadership Through Portfolio Innovations at AF Symposium Johnson & Johnson is announcing new portfolio innovations in addition to compelling clinical evidence in atrial fibrillation (AFib) at the 31st Annual AF Symposium in Boston.…
EYLEA HD® (aflibercept) 8 mg Data Presented at Angiogenesis 2026 Highlight Robust Clinical Profile in Treating Serious Retinal Diseases Regeneron Pharmaceuticals, Inc. today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration)…
Johnson & Johnson Secures CHMP Positive Opinion for AKEEGA®—a Dual-Action Tablet Combining Niraparib and Abiraterone Acetate—for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Patients with BRCA1/2 Mutations Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use…
WuXi Biologics and Sinorda Biomedicine Forge Strategic Partnership to Advance Development and Manufacturing of Innovative Bispecific Antibodies WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the…
Intellia Therapeutics Announces FDA Lifts Clinical Hold on MAGNITUDE-2 Phase 3 Trial for ATTRv-PN Intellia Therapeutics, Inc., a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has removed…
BioMarin Moves to Strengthen BalanceBioMarin Announces Proposed Private Offering of Senior Notes and New Senior Secured Term Loan Syndication BioMarin Pharmaceutical Inc. announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured…
GSK’s RSV Vaccine, Arexvy, Gains European Approval for Use in All Adults Aged 18 and Older GSK plc today announced that its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, has been approved by the European Commission* (EC) for use…
Aspect Biosystems and Novo Nordisk Advance Partnership to Develop Curative Diabetes Therapies Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes. Since 2023, Aspect andNovo Nordisk…
Bristol Myers Squibb Teams Up with Microsoft to Accelerate AI-Powered Early Lung Cancer Detection Bristol Myers Squibb, a global leader in oncology, today announced an agreement with Microsoft, a market leader in AI-powered radiology and clinical workflow technologies, aiming to…
Bioscience Association Manitoba Joins Premier’s Workforce Development Subcommittee to Shape the Future of Talent and Economic Growth In a significant step toward aligning Manitoba’s economic strategy with the demands of a rapidly evolving global marketplace, the Bioscience Association Manitoba (BAM)…
New Data Shows CAPLYTA® May Help Adults with MDD Achieve Remission Johnson & Johnson today announced a new analysis of Phase 3 data which found CAPLYTA® (lumateperone), in combination with an antidepressant, showed significantly greater remission rates in adults with major depressive…
Johnson & Johnson Launches Mobile Simulator App to Empower Breast Augmentation Patients Johnson & Johnson announced the U.S. launch of the Arbrea Breast Simulator Surgeon App for Mentor, a digital consultation tool available on tablets and smart phones that helps plastic…